Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

9-ING-41 is a small molecule potent selective GSK-3β inhibitor with antitumor activity. This study investigates 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). Patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma [ACC]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.

Start Date18 Dec 2030

Sponsor / Collaborator

Actuate Therapeutics, Inc.Startup

NCT05403723

/ SuspendedPhase 1IIT

A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination with Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

Start Date31 Dec 2025

Sponsor / Collaborator

University of Maryland Baltimore

[+1]

NCT06291064

/ Not yet recruitingPhase 2IIT

TreAtment Response and Omic-Markers in Triple-Negative Breast CAncer Patients Receiving Standard of Care Chemotherapy (TARMAC)

The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC).
All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis.

Start Date01 Nov 2025

Sponsor / Collaborator

The University of Chicago

100 Clinical Results associated with Carboplatin

100 Translational Medicine associated with Carboplatin

100 Patents (Medical) associated with Carboplatin

27,633

Literatures (Medical) associated with Carboplatin

31 Dec 2025·NMC case report journal

A Primary Spinal Intramedullary Mixed Germ Cell Tumor: A Case Report and Literature Review

Article

Author: SHIMAUCHI-OHTAKI, Hiroya ; HORIGUCHI, Keishi ; HIRATO, Junko ; NAKATA, Satoshi ; HONDA, Fumiaki ; YOKOO, Hideaki ; GOTO, Yuta ; OYA, Soichi ; TOMOMASA, Ran ; NAKAMURA, Shunsuke

Central nervous system germ cell tumors are rare and account for 2% to 3% of all central nervous system tumors in Japan. Here, we report an extremely rare case of a primary spinal intramedullary mixed germ cell tumor. A 33-year-old man presented with a chief report of dysuria and numbness in the right lower extremity. Magnetic resonance imaging revealed a mass lesion on the left side of the intramedullary spinal cord at the Th10-11 vertebral body level with hyperintensity on T2-weighted images, isointensity on T1-weighted images, and uniform contrast in gadolinium. Cerebrospinal fluid examination revealed a few atypical cells. Although tumor removal using the posterior median sulcus approach was attempted, only a biopsy was performed because intraoperative rapid pathology suggested a possible diagnosis of germinoma. Permanent pathology revealed a mixed germ cell tumor (mainly comprising a germinoma with a yolk sac tumor). Postoperatively, cerebrospinal irradiation and 8 courses of the carboplatin and etoposide regimen were administered. No recurrence or new lesions were observed on magnetic resonance imaging at 94 months postoperatively. Our extensive literature search found only 4 cases of a mixed germ cell tumor of primary intramedullary origin in the spinal cord. Most spinal germ cell tumors described in the literature are either germinomas or mature teratomas; however, mixed germ cell tumors can also occur, albeit infrequently. Although additional cases need to be accumulated, our case suggests that yolk sac elements in spinal mixed germ cell tumors might not be directly associated with poor life expectancy.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare

Article

Author: Bernauer, Mark ; Roth, Joshua A. ; Dorman, Stephanie ; Kratochvil, David

BACKGROUND:

Biosimilars to originator bevacizumab (Avastin), such as bevacizumab-bvzr (Zirabev), can deliver substantial savings and/or expanded access to biologic therapy for patients with metastatic colorectal (mCRC) and non-squamous non-small cell lung cancer (mNSCLC). The objective of this study is to explore the cost-efficiency and budget-neutral expanded access of bevacizumab-bvzr in mCRC and mNSCLC in Medicare.

METHODS:

We developed a Medicare payer perspective simulation model of patients treated for mCRC and mNSCLC to estimate cost-savings from converting bevacizumab (originator) to bevacizumab-bvzr or alternative biosimilars such as bevacizumab-awwb, -maly, and -abcd. The target patient population receiving annual first-line systemic therapy was calculated using Medicare enrollment data, SEER cancer incidence rates in patients age ≥65, and an assumption that 39.3% and 77.2% of new diagnoses receive systemic therapy for mCRC and mNSCLC respectively based on recent evidence. 76.0% of systemically treated mCRC patients and 11.4% of incident mNSCLC patients were expected to be treated with bevacizumab-based regimens based on recent evidence. Costs were derived from the 2024 Average Sales Price (ASP). Results include per-patient per-month (PPPM) cost savings (vs. originator), total monthly savings in the cohort, and number needed to convert (NNC) to biosimilar to fund the treatment of an additional 100 patients.

RESULTS:

PPPM savings from conversion to bevacizumab-bvzr were $4,205 in mCRC and $8,410 in mNSCLC. In 100% conversion scenarios, full cohort monthly savings were $27,664,432 in mCRC (n = 6,579) and $32,319,323 in mNSCLC (n = 3,843), respectively. At 100% conversion, monthly savings from biosimilar conversion could fund up to 13,887 additional mCRC patient-months of treatment with bevacizumab-bvzr + FOLFOX, and up to 8,959 additional mNSCLC patient-months of treatment with bevacizumab-bvzr + paclitaxel + carboplatin. In mCRC and mNSCLC the biosimilar NNC from the originator was 47 and 43, respectively. The biosimilar NNC from other biosimilars ranged from 60-4,564 and 55-4,422 for mCRC and NSCLC, respectively.

CONCLUSION:

In the first cost-efficiency and expanded access study of biosimilar bevacizumab in mCRC and mNSCLC, we find that bevacizumab-bvzr-based regimens can result in substantial cost savings relative to originator-based first line treatment in Medicare. These cost savings could be reinvested to treat a substantial number of additional patients with mCRC or mNSCLC, or fund other costs of care in Medicare, on a budget-neutral basis.

01 Dec 2025·CHILDS NERVOUS SYSTEM

Holocord intramedullary pilocytic astrocytoma mimicking holocord spinal abscess: a case report and literature review

Review

Author: Erguven, Merve ; Sabanci, Pulat Akin ; Dolen, Duygu ; Gulsever, Cafer Ikbal ; Unverengil, Gokcen

PURPOSE:

This report aims to present a case of a child with holocord pilocytic astrocytoma and review the existing literature to provide insights into current management strategies.

CASE PRESENTATION:

An 11-month-old patient presented with progressive quadriplegia and was initially diagnosed with a spinal abscess. MRI revealed a heterogeneously enhancing cystic intramedullary lesion extending from the cervicomedullary region to the conus medullaris. The patient underwent an emergent T10-L1 total laminectomy and midline myelotomy for presumed abscess drainage. Intraoperative findings, however, were inconsistent with an abscess, suggesting a neoplastic process. Postoperative MRI indicated persistent spinal cord compression and histopathological examination showed no leukocytes or microorganisms. A second surgery the following day extended the laminectomy to T3, achieving gross total resection. Pathology confirmed a grade I pilocytic astrocytoma. Given the patient's age, chemotherapy with vincristine and carboplatin was initiated, as radiotherapy was unsuitable. Early physical therapy was commenced, resulting in significant neurological improvement to 4/5 muscle strength in all extremities according to the Medical Research Council (MRC) scale in the first year. Chemotherapy was discontinued due to systemic complications. At the 1-year follow-up, MRI demonstrated no tumor recurrence.

CONCLUSION:

The management of holocord pilocytic astrocytomas presents significant challenges, particularly in pediatric patients. While surgical resection remains the cornerstone of treatment, the role of chemotherapy requires further investigation. This case underscores the necessity of a multidisciplinary approach and highlights the potential for favorable outcomes with appropriate intervention.

940

News (Medical) associated with Carboplatin

18 hours ago

·www.prnewswire.com

New Hope for Advanced Cancer Patients: SAGE Showcases Treatment-Matching via Functional Precision Oncology at AACR 2025

REDWOOD CITY, Calif., April 24, 2025 /PRNewswire/ -- SageMedic Corp. (SAGE), a Silicon Valley pioneer in Functional Precision Oncology, announces significant advancements in personalized cancer therapy using its innovative SAGE Oncotest™, a groundbreaking ex-vivo 3D microtumor assay that evaluates live tumor tissue responses to a comprehensive range of FDA-approved therapies. This novel approach is being presented at the American Association for Cancer Research (AACR) Annual Meeting, held in Chicago from April 25–30, 2025. SAGE's recent findings, highlighted in a poster titled "Heterogeneity of ex-vivo Tumor Responses in Primary Ovarian Cancer Tissues," demonstrate how every ovarian cancer is biologically distinct, with substantial variations in tumor responses to standard therapies like carboplatin and paclitaxel. The SAGE Oncotest™, uniquely capable of preserving the complexity of tumor heterogeneity and microenvironment, provides actionable insights within just 7–10 days—a critical step toward truly personalized cancer treatment. Unlike genomic tests that yield actionable results in only 26% of cases, the SAGE Oncotest™ delivers them in 88%. "Our platform represents a transformative leap in Functional Precision Oncology," stated Dr. Chris Apfel, Chair and CEO of SageMedic. "Every tumor is distinctively different, and genomic testing alone often fails to capture the full complexity of an individual patient's biology. Functional Precision Oncology measures how a patient's actual tumor responds to therapies. This enables SAGE concierge oncologists to personalize treatment, reduce toxic and ineffective drugs, and improve outcomes. This is especially vital for advanced cancer patients who have run out of options." In short, as a cornerstone of novel Functional Precision Oncology approaches, the SAGE Oncotest™—while not yet covered by insurance—provides a much-needed personalized option for late-stage cancer patients when standard of care treatments have failed, offering new hope where few options remain. For more information, visit . Media Contact: Mara Quigley 661.255.8283 [email protected] SOURCE SageMedic Corp. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AACR

24 Apr 2025

·www.fda.gov

FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma

On April 23, 2025, the Food and Drug Administration approved penpulimab-kcqx (Akeso Biopharma Co., Ltd.) with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.Full prescribing information for penpulimab-kcqx will be posted on Drugs@FDA.Efficacy and SafetyEfficacy of penpulimab-kcqx with cisplatin or carboplatin and gemcitabine was evaluated in Study AK105-304 (NCT04974398), a randomized, double-blind, multi-center trial in 291 patients with recurrent or metastatic NPC who had not received previous systemic chemotherapy for recurrent or metastatic disease. Patients were randomized (1:1) to receive either penpulimab-kcqx with cisplatin or carboplatin and gemcitabine, followed by penpulimab-kcqx, or placebo with cisplatin or carboplatin and gemcitabine, followed by placebo. Chemotherapy regimens are described in the full prescribing information.The primary efficacy outcome measure was progression-free survival (PFS), as assessed by a Blinded Independent Review Committee according to RECIST v1.1. Overall survival (OS) was a key secondary endpoint. Median PFS was 9.6 months (95% CI: 7.1, 12.5) in the penpulimab-kcqx arm and 7.0 months (95% CI: 6.9, 7.3) in the placebo arm (hazard ratio [HR] 0.45 [95% CI: 0.33, 0.62], two-sided p-value <0.0001), with 31% and 11% of patients alive and progression-free after 12 months of follow-up in the penpulimab-kcqx and placebo arms, respectively. While OS results were immature, with 70% of pre-specified deaths for the final analysis reported, no detrimental trend was observed.Efficacy of single-agent penpulimab-kcqx was evaluated in Study AK105-202 (NCT03866967), an open-label, multicenter, single-arm trial conducted in a single country. The trial included a total of 125 patients with unresectable or metastatic non-keratinizing NPC who had disease progression after platinum-based chemotherapy and at least one other line of therapy. Patients received penpulimab-kcqx until disease progression or unacceptable toxicity, for a maximum of 24 months.The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR) according to RECIST v1.1 as assessed by an Independent Radiology Review Committee. The ORR was 28% (95% CI: 20, 37) and median DOR was not reached (95% CI: 9.2, not estimable).Immune-mediated adverse reactions occurred with penpulimab-kcqx including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, and skin adverse reactions. The most common adverse reactions (≥20%) for penpulimab-kcqx with cisplatin or carboplatin and gemcitabine were nausea, vomiting, hypothyroidism, constipation, decreased appetite, decreased weight, cough, COVID-19 infection, fatigue, rash, and pyrexia. The most common adverse reactions (≥20%) for single-agent penpulimab-kcqx were hypothyroidism and musculoskeletal pain. Fatal adverse reactions occurred in 1% of patients, including a case each of pneumonitis, septic shock, colitis, and hepatitis.The recommended penpulimab-kcqx dose with cisplatin or carboplatin and gemcitabine is 200 mg every three weeks until disease progression or unacceptable toxicity, for a maximum of 24 months. The recommended single-agent penpulimab-kcqx dose for previously treated NPC is 200 mg every two weeks until disease progression or unacceptable toxicity, for a maximum of 24 months.Expedited ProgramsThis review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.This application was granted fast track designation, breakthrough designation, and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088.For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.Follow the Oncology Center of Excellence on X: @FDAOncology.

Clinical ResultFast TrackOrphan DrugDrug Approval

23 Apr 2025

·www.prnewswire.com

Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting

SAN FRANCISCO and SUZHOU,China, April 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its innovative bispecific antibodies and ADC molecules, including oral presentations for IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 from May 30 to June 3, 2024, in Chicago, Illinois, U.S. Dr. Hui Zhou, Senior Vice President of Innovent, stated: "We are delighted to announce that at 2025 ASCO Annual Meeting, the first wave of three indications under development for IBI363—melanoma, colorectal cancer(CRC), and non-small cell lung cancer (NSCLC)—have all been accepted for oral presentations, highlighting the significant attention garnered by the next-generation bispecific antibodies, in particular PD-1-based immunotherapy. Additionally, following its oral presentation at ESMO Asia last December, the Phase 1b data of IBI343 in pancreatic cancer has once again secured an oral presentation at ASCO, further solidifying its potential in this challenging therapeutic area. The maturing PoC data for these innovative candidates has strengthened our confidence in advancing them into pivotal-stage development, with the goal of unlocking their clinical value for global unmet clinical needs. As one of the few biopharmaceutical companies with both the advanced technology platforms and robust pipeline in "IO+ADC" areas, Innovent will continue to make breakthroughs in the field of cancer treatment, and is committed to providing physicians and patients with more innovative, effective and safe treatment options." Details on the abstracts are listed below: Oral Presentation 1. Presentation Title: Efficacy and safety results of a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, IBI363, in patients with immunotherapy-treated, advanced acral and mucosal melanoma Abstract Number: 2502 Session Type: Oral Abstract Session Title: Developmental Therapeutics-Immunotherapy Session Date & Time: 5/31/2025 3:00 PM-6:00 PM CDT Presenter: Jun Guo, MD, Beijing Cancer Hospital 2. Presentation Title: Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancer Abstract Number: 104 Session Type: Oral Abstract Session Title: Clinical Science Symposium—Turning "Cold" Tumors "Hot" Session Date & Time: 6/1/2025 9:45 AM-11:15 AM CDT Presenter: Zhenyu Lin, MD, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 3. Presentation Title: First-in-class PD-1/IL-2α-bias bispecific antibody, IBI363, in patients with advanced immunotherapy-treated non-small cell lung cancer (NSCLC) Abstract Number: 8509 Session Type: Oral Abstract Session Title: Clinical Science Symposium—Two Targets, One Goal: The Potential for Bispecific Antibodies in Thoracic Malignancies Session Date & Time: 6/3/2025 9:45 AM-11:15 AM CDT Presenter: Jianya Zhou, MD, The First Affiliated Hospital, Zhejiang University School of Medicine 4. Presentation Title: Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): results from a Phase 1 dose expansion cohort evaluating IBI343 Abstract Number: 4017 Session Type: Rapid Oral Abstract Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Session Date & Time: 6/2/2025 11:30 AM-1:00 PM CDT Presenter: Xianjun Yu, MD, Fudan University Shanghai Cancer Center 5. Presentation Title: Sintilimab (anti-PD-1) plus ifosfamide, carboplatin and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind Phase 3 study (ORIENT-21) Abstract Number: 7007 Session Type: Oral Abstract Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Session Date & Time: 5/30/2025 2:45 PM-5:45 PM CDT Presenter: Peng Liu,MD, Cancer Hospital, Chinese Academy of Medical Sciences 6. Presentation Title: Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: A prospective, randomized controlled trial (SPRING-01) Abstract Number: 3519 Session Type: Rapid Oral Abstract Session Title: Gastrointestinal Cancer-Colorectal and Anal Session Date & Time: 6/1/2025 11:30 AM-1:00 PM CDT Presenter：Changqing Jing, MD, Shandong Provincial Hospital 7. Presentation Title: Dynamic circulating tumor DNA-driven, risk-adapted systematic therapy in n as opharyngeal carcinoma: The EP-STAR trial Abstract Number: 6010 Session Type: Oral Abstract Session Title: Clinical Science Symposium -Biomarker-Driven Adaptive Therapy: New Horizons in Head and Neck Cancer Session Date & Time: 6/2/2025 3:00 PM-4:30 PM CDT Presenter: Ying Sun, MD, Sun Yat-sen University Cancer Center Poster Presentation 1. Presentation Title: A multicenter, randomized, controlled, open-label, Phase 2 study of the PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 in mucosal and acral melanoma: Trial in Progress Abstract Number: TPS9594 Session Type: Poster Session Title: Melanoma/Skin Cancers Session Date & Time: 6/1/2025 9:00 AM-12:00 PM CDT Presenter: Bin Lian, MD, Peking University Cancer Hospital & Institute 2. Presentation Title: IBI354, an anti-HER2 antibody-drug conjugate, in patients with locally advanced unresectable or metastatic ovarian cancers: updated results from a Phase 1 trial Abstract Number: 5565 Session Type: Poster Session Title: Gynecologic Cancer Session Date & Time: 6/1/2025 9:00 AM-12:00 PM CDT Presenter: Jin Shu, MD, Chongqing University Cancer Hospital 3. Presentation Title: IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients with HER2-positive breast cancer (BC) and other solid tumors: Updates from a Phase 1 study Abstract Number: 1029 Session Type: Poster Session Title: Breast Cancer—Metastatic Session Date & Time: 6/2/2025 9:00 AM-12:00 PM CDT Presenter: Charlotte Rose Lemech, BSc, FRACP, MBBS , Scientia Clinical Research 4. Presentation Title: Safety and efficacy of the anti-TROP2 antibody-drug conjugate (ADC) IBI130 in patients with advanced triple-negative breast cancer (TNBC) and other solid tumors: Results from the Phase 1 study Abstract Number: 1102 Session Type: Poster Session Title: Breast Cancer—Metastatic Session Date & Time: 6/2/2025 9:00 AM-12:00 PM CDT Presenter: Fan Wu, MD, Fujian Cancer Hospital 5. Presentation Title: A multiregional, randomized, controlled, open-label, Phase 3 study of the anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) arcotatug tavatecan (IBI343) in gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Trial in Progress Abstract Number: TPS4201 Session Type: Poster Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Session Date & Time: 5/31/2025 9:00 AM-12:00 PM CDT Presenter: Lin Shen, MD, Beijing Cancer Hospital 6. Presentation Title: Phase 2 trial of transarterial chemoembolization followed by sintilimab (anti-PD-1), oxaliplatin, and S-1 combined with either trastuzumab (HER-2 positive) or apatinib (HER-2 negative) as first-line therapy for gastric cancer with liver metastases. Abstract Number: 4050 Session Type: Poster Session Title: Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary Session Date & Time: 5/31/2025 9:00 AM-12:00 PM CDT Presenter: Dan Sha, MD, Shandong Provincial Hospital *Abstracts of TYVYT ®(sintilimab) are from investigator-initiated clinical trials (IIT), except one abstract, #7007. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Statement: (1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). (2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. SOURCE Innovent Biologics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1ASCOImmunotherapyClinical ResultPhase 2

100 Deals associated with Carboplatin

External Link

KEGG	Wiki	ATC	Drug Bank
D01363	Carboplatin	L01XA02	DB00958

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Endometrial Carcinoma	Japan	Clinigen KK	24 Jun 2024
Breast Cancer	Japan	Clinigen KK	25 Nov 2011
Breast Cancer	Japan	Bristol-Myers Squibb KK	25 Nov 2011
Ewing Sarcoma	Japan	Clinigen KK	15 Sep 2005
Ewing Sarcoma	Japan	Bristol-Myers Squibb KK	15 Sep 2005
Hepatoblastoma	Japan	Bristol-Myers Squibb KK	15 Sep 2005
Hepatoblastoma	Japan	Clinigen KK	15 Sep 2005
Neuroblastoma	Japan	Clinigen KK	15 Sep 2005
Neuroblastoma	Japan	Bristol-Myers Squibb KK	15 Sep 2005
Retinoblastoma	Japan	Clinigen KK	15 Sep 2005
Retinoblastoma	Japan	Bristol-Myers Squibb KK	15 Sep 2005
Wilms Tumor	Japan	Clinigen KK	15 Sep 2005
Wilms Tumor	Japan	Bristol-Myers Squibb KK	15 Sep 2005
Non-Small Cell Lung Cancer	Japan	Bristol-Myers Squibb KK	27 Jul 2000
Non-Small Cell Lung Cancer	Japan	Clinigen KK	27 Jul 2000
Squamous Cell Carcinoma of Head and Neck	China	Bristol-Myers Squibb Srl	28 Jul 1997
Head and Neck Neoplasms	Japan	Clinigen KK	30 Mar 1990
Head and Neck Neoplasms	Japan	Bristol-Myers Squibb KK	30 Mar 1990
Lymphoma	Japan	Clinigen KK	30 Mar 1990
Lymphoma	Japan	Bristol-Myers Squibb KK	30 Mar 1990

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioblastoma Multiforme	Phase 3	United States	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	Belgium	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	France	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	Germany	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	Italy	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	Netherlands	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	Spain	CarThera SAS	29 Jan 2024
Glioblastoma Multiforme	Phase 3	Switzerland	CarThera SAS	29 Jan 2024
Recurrent Glioblastoma	Phase 3	United States	CarThera SAS	29 Jan 2024
Recurrent Glioblastoma	Phase 3	Belgium	CarThera SAS	29 Jan 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04512430 (CTgov)	Phase 2	Non-Small Cell Lung Cancer	4	Carboplatin+Pemetrexed+Atezolizumab+Bevacizumab	zcfzucijqp = zjnrbnjhuy yevvjkxvcw (zslmyesiht, pgbdjgohdd - vdmprjcjvb) View more	-	02 Apr 2025
NCT00513786 (CTgov)	Phase 2	Advanced Endometrial Carcinoma	38	Carboplatin+Paclitaxel+Bevacizumab	glgecucwvn(tqhlqddjba) = fuitcimdfq sasyycnipa (gijllganon, wzbkbuxomw - owjvqvwziz) View more	-	28 Mar 2025
NCT04158141 (CTgov)	Phase 3	Malignant Pleural Mesothelioma	16	Pleurectomy+Carboplatin+Pemetrexed+cisplatin+Pemetrexed Disodium (Arm I (Step 1: Chemotherapy, P/D: Step 2: no Treatment))	iqwkzzhyur = jhfuzgvzbi qkvdtiijud (nrnxcxrxhn, ecgdvykuff - fygrnsolkz) View more	-	19 Feb 2025
NCT04158141 (CTgov)	Phase 3	Malignant Pleural Mesothelioma	16	Intensity-Modulated Radiation Therapy+Carboplatin+Pemetrexed+cisplatin+Pemetrexed Disodium (Arm II (Step 1: Chemotherapy, P/D, Step 2: IMRT/PBS))	iqwkzzhyur = ywrrwducje qkvdtiijud (nrnxcxrxhn, wgklbgdwdh - btddfvbpnm) View more	-	19 Feb 2025
NCT03980925 (GETNE T1913, CTgov)	Phase 2	Neuroendocrine neoplasm of gastrointestinal tract \| Gastro-Enteropancreatic Neuroendocrine Tumor	37	Nivolumab+Etoposide+Carboplatin	xnjgudleau = cweifdpavg dvqesazfsu (eaazcjvmjk, iypdypkcmm - jeofqyzoti) View more	-	13 Jan 2025
NCT04923776 (CTgov)	Phase 2	Extensive stage Small Cell Lung Cancer	2	Stereotactic Body Radiation Therapy (SBRT)+Etoposide+Carboplatin+Atezolizumab	wioacjxjzn(sfzyukishq) = eskawllelb ejdijyemdw (boiadxkuhj, gwlubwcndv - bsqtqblwjl) View more	-	30 Dec 2024
ESMO_ASIA2024 Manual	Not Applicable	Head and Neck Neoplasms	104	Docetaxel plus Cisplatin	ytiihmdntc(zzlfxwrguj) = gglwdygyou qodskazoyj (ypvrtuieom ) View more	Similar	07 Dec 2024
ESMO_ASIA2024 Manual	Not Applicable	Head and Neck Neoplasms	104	Paclitaxel plus Carboplatin	ytiihmdntc(zzlfxwrguj) = ckhikuvpbg qodskazoyj (ypvrtuieom ) View more	Similar	07 Dec 2024
NCT05786430 (LUCAS, ESMO_ASIA2024) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	54	Lazertinib + Pemetrexed + Carboplatin	umkfogdjbl(ggxpafuwga) = sedjhxfkow mgqygdcdek (fasobdtrpt, 5.16 - 9.56) View more	Positive	07 Dec 2024
NCT03081689 (NADIM Study \| NADIM phase II trial \| ###DELETE \| 2016-003732-20 \| NADIM \| NADIM study-SLCG, CTgov)	Phase 2	Non-small cell lung cancer stage IIIA	46	Nivolumab 360 mg+Carboplatin AUC 6+Paclitaxel 200mg/m2	crrwsywbxi = vktmjipmwg ffmirydpfx (lnbeufeyzw, edqrigqbzi - gtbhimicxq) View more	-	04 Dec 2024
NCT04951115 (CTgov)	Phase 2	Small Cell Lung Cancer	6	Stereotactic Body Radiotherapy+Etoposide+Carboplatin+Cisplatin+Durvalumab	noyzrbrqec = zpmnifmntu nctepoztzg (upsfcfbvmd, bromirgvvp - nadpfjipok) View more	-	26 Nov 2024
NCT03393884 (OVATION-2, SITC2024) Manual	Phase 1/2	Ovarian Epithelial Carcinoma First line	117	IMNN-001 + NACT	hjdfhaphgp(wjynpxkvpx) = pdiueyqwrl adccphqahd (avwnpndrnu ) View more	Positive	08 Nov 2024
NCT03393884 (OVATION-2, SITC2024) Manual	Phase 1/2	Ovarian Epithelial Carcinoma First line	117	NACT	hjdfhaphgp(wjynpxkvpx) = yadypocuti adccphqahd (avwnpndrnu ) View more	Positive	08 Nov 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis